Our Purpose

Polaris Genomics is decoding the biological fingerprints of mental health to advance the discovery and development of tools and diagnostics for a range of conditions, including PTSD, depression/anxiety, ADHD, TBI, and substance use disorder.

 

Drawing upon decades of experience in biomedical technology, public health, & molecular biology, Polaris Genomics was founded to address the mental health crisis that was resulting in 22 veteran suicides each day. Partnering with the Illumina Accelerator & scientists from Mount Sinai & the Max Planck Institute of Psychiatry, the team developed the first-to-market, patented genomic biomarker assay to identify PTSD risk in 2018.

Polaris Genomics harnesses AI-powered genomics to define the biological underpinnings of mental health, develop objective diagnostics, and unlock novel therapeutics.

At the junction of precision medicine and mental health, our vision is to reduce suicide, stigma, and suffering in silence.

 

Our founding mission to harness precision technology and genomic diagnostics to improve the lives of U.S. military service members and veterans living with mental health conditions, such as post-traumatic stress disorder (PTSD), remains at our roots.

 

Answering a calling to serve, Polaris has since expanded its mission to develop more genomics-based discovery and screening tools to encompass a broader range of mental health conditions and populations, including:

• • Veterans and Military Service Members,
  • First responders, frontline workers, and individuals in high-risk occupations, and
  • Trauma-exposed communities at large.